<DOC>
	<DOCNO>NCT00038636</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness high dose ABT-378/ritonavir</brief_summary>
	<brief_title>A Study Two Different Doses ABT-378/Ritonavir HIV-Infected Patients Who Have Taken Protease Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion : HIV positive Are least 18 year old Subject treat active AIDSdefining opportunistic infection within 15 day screen HIV RNA level &gt; 1000 copies/mL Previous therapy least one protease inhibitor , least one nonnucleoside reverse transcriptase inhibitor least one nucleoside reverse transcriptase inhibitor Exclusion : Subject pregnant breastfeeding Subject receive investigational drug within 30 day prior screen Have history pancreatitis History intolerance ritonavir Abnormal laboratory test screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>HIV</keyword>
</DOC>